NCT00086710已完成1 期
An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Trimeris
- 入组人数
- 26
- 试验地点
- 2
研究概览
简要总结
A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesHealthy MalesDiabetes Mellitus, Type 2NCT00475371Mannkind Corporation26
已完成
4 期
Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentHIV InfectionsNCT00005018Glaxo Wellcome150
已完成
2 期
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease InhibitorsHIV InfectionsNCT00002361Merck Sharp & Dohme LLC30
已完成
4 期
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM StudyHIV InfectionsNCT03067285Fundacion SEIMC-GESIDA39
已完成
1 期
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected ChildrenHIV InfectionsNCT00000901National Institute of Allergy and Infectious Diseases (NIAID)24